Comparative Pharmacology
Head-to-head clinical analysis: MARCAINE HYDROCHLORIDE versus POLOCAINE MPF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARCAINE HYDROCHLORIDE versus POLOCAINE MPF.
MARCAINE HYDROCHLORIDE vs POLOCAINE-MPF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, reversibly inhibiting nerve impulse propagation, particularly in sensory fibers.
Polocaine-MPF (mepivacaine hydrochloride) is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby preventing the initiation and propagation of nerve impulses. This results in reversible loss of sensation in the area of administration.
Adults: 0.5% solution infiltrated up to 175 mg (35 mL) for minor procedures; for major procedures, up to 225 mg (45 mL) with epinephrine. Repeat doses at 3-hour intervals. Maximum dose 400 mg with epinephrine.
Adults: 1-2 cartridges (1.8 mL each) of 2% lidocaine with 1:100,000 epinephrine administered via local infiltration or nerve block, not to exceed 7 mg/kg (maximum 500 mg) for lidocaine.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 to 3.5 hours in adults; may be prolonged in neonates (8-12 hours) or patients with hepatic impairment.
Terminal elimination half-life: 1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 4-6 hours) and severe renal impairment. Clinical context: short half-life supports continuous infusion for sustained effect.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Metabolites are excreted renally, with a small amount in feces via biliary elimination.
Renal: >90% as metabolites, primarily 4-hydroxy-2',6'-dimethylacetanilide and pipecoloxylidide; unchanged drug <5%. Biliary/fecal: <5%.
Category C
Category C
Local Anesthetic
Local Anesthetic